Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

May 8, 2024

https://www.globenewswire.com/news-release/2024/05/08/2877995/8624/en/Trinity-Biotech-Welcomes-Avinash-Kale-as-Continuous-Glucose-Monitor-Programme-Director-to-Advance-Innovation-and-Development.html

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM solution to the global market.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.